Free Trial

Zentalis Pharmaceuticals (ZNTL) Competitors

Zentalis Pharmaceuticals logo
$1.27 +0.08 (+6.72%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.27 0.00 (0.00%)
As of 07/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZNTL vs. PRTA, TERN, PRME, HUMA, AQST, SNDL, HRTX, AURA, ALT, and CTOR

Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), Aquestive Therapeutics (AQST), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Altimmune (ALT), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.

Zentalis Pharmaceuticals vs. Its Competitors

Prothena (NASDAQ:PRTA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

97.1% of Prothena shares are held by institutional investors. 9.2% of Prothena shares are held by company insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Prothena had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 1 mentions for Prothena and 0 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.00 beat Prothena's score of -0.16 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Prothena Neutral
Zentalis Pharmaceuticals Neutral

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Prothena's net margin of -79.94%. Prothena's return on equity of -21.61% beat Zentalis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Prothena-79.94% -21.61% -19.32%
Zentalis Pharmaceuticals N/A -65.48%-51.05%

Prothena presently has a consensus target price of $31.50, suggesting a potential upside of 383.13%. Zentalis Pharmaceuticals has a consensus target price of $8.37, suggesting a potential upside of 558.79%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prothena
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
Zentalis Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Prothena has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.

Prothena has higher revenue and earnings than Zentalis Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$135.16M2.60-$122.31M-$2.08-3.13
Zentalis Pharmaceuticals$67.43M1.36-$165.84M-$3.13-0.41

Summary

Prothena beats Zentalis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZNTL vs. The Competition

MetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$85.62M$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E Ratio-0.4120.8026.9620.11
Price / Sales1.36286.27430.20119.79
Price / CashN/A41.1936.8257.86
Price / Book0.277.487.985.56
Net Income-$165.84M-$55.04M$3.16B$248.40M
7 Day Performance2.42%2.44%2.39%4.67%
1 Month Performance-14.77%1.90%2.18%6.64%
1 Year Performance-69.98%4.35%33.82%21.31%

Zentalis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZNTL
Zentalis Pharmaceuticals
1.5507 of 5 stars
$1.27
+6.7%
$8.37
+558.8%
-69.6%$85.62M$67.43M-0.41160
PRTA
Prothena
3.0398 of 5 stars
$6.07
-0.2%
$31.50
+418.9%
-67.7%$326.75M$135.16M-2.92130
TERN
Terns Pharmaceuticals
3.7045 of 5 stars
$3.73
-2.6%
$15.63
+318.9%
-39.8%$325.78MN/A-3.4240
PRME
Prime Medicine
4.0534 of 5 stars
$2.47
+2.1%
$10.08
+308.2%
-25.3%$324.30M$3.85M-1.20234Options Volume
High Trading Volume
HUMA
Humacyte
2.7442 of 5 stars
$2.09
-1.4%
$11.71
+460.5%
-54.7%$324.20M$1.57M-3.03150News Coverage
Gap Up
AQST
Aquestive Therapeutics
1.244 of 5 stars
$3.31
+1.8%
$10.14
+206.4%
+53.3%$322.82M$54.23M-5.61160
SNDL
SNDL
3.513 of 5 stars
$1.21
-1.6%
$3.63
+199.6%
-29.9%$317.96M$671.81M-4.172,516
HRTX
Heron Therapeutics
3.8245 of 5 stars
$2.07
-3.3%
$5.00
+141.5%
-25.9%$315.80M$144.29M-34.50300Positive News
AURA
Aura Biosciences
1.874 of 5 stars
$6.26
-0.3%
$22.00
+251.4%
-14.6%$314.69MN/A-3.2950Positive News
ALT
Altimmune
2.2151 of 5 stars
$3.87
+10.6%
$19.00
+391.0%
-33.5%$313.90M$20K-3.0750High Trading Volume
CTOR
Citius Oncology
0.3927 of 5 stars
$4.35
-3.3%
$3.00
-31.0%
N/A$311.24MN/A0.00N/A

Related Companies and Tools


This page (NASDAQ:ZNTL) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners